Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial

(2014) Todd J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

(2013) et al.   EUROPEAN HEART JOURNAL

Use of Niacin in the United States and Canada

(2013) Cynthia A. Jackevicius et al.   JAMA Internal Medicine

Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms

(2012) Janet E. Digby et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation

(2012) Sonia Philipose et al.   PLoS One

Prostaglandins and Inflammation

(2011) Emanuela Ricciotti et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

ESC/EAS Guidelines for the management of dyslipidaemias

(2011) Alberico L. Catapano et al.   ATHEROSCLEROSIS

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

The effects of laropiprant, a selective prostaglandin D2receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

(2011) Aimee Dallob et al.   PLATELETS

Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome

(2010) S. Fazio et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

(2010)   LANCET

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

(2010) Eseng Lai et al.   PLATELETS

The in vitro effects of niacin on platelet biomarkers in human volunteers

(2010) Alex Malinin et al.   THROMBOSIS AND HAEMOSTASIS

Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients

(2009) Harold E. Bays et al.   CLINICAL THERAPEUTICS

Major Lipids, Apolipoproteins, and Risk of Vascular Disease

(2009) The Emerging Risk Factors Collaboration*   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Laropiprant in Combination With Extended-Release Niacin Does Not Alter Urine 11-Dehydrothromboxane B2, a Marker of In Vivo Platelet Function, in Healthy, Hypercholesterolemic, and Diabetic Subjects

(2009) Brett Lauring et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Niacin on Glucose Control in Patients With Dyslipidemia

(2009) Ronald B. Goldberg et al.   MAYO CLINIC PROCEEDINGS

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

(2008) D. Maccubbin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE